Targeting Barrier Reinforcement and MAPK Inhibition: Recombinant Mucin-Type Collagen Tandems Ameliorate Inflammation in TNF-α/IFN-γ-Induced Atopic Dermatitis-like HaCaT Keratinocytes.

The recombinant multicopy tandem mucin-type collagen is one of the most promising multifunctional enhanced collagen materials in green biomanufacturing. Based on multicopy tandem of mucin-type sequence (GAPGAPGSQGAPGLQ) derived from human COL1α1, this paper analyzes how the physical and chemical characteristics and structure of proteins are influenced by the biosynthetic different multicopy integration (CF15 series collagens) in Escherichia coli. The CF15 series collagens not only stimulate cellular proliferation but also significantly enhance the integrity and functionality of the cellular barrier. Herein, by the TNF-α/IFN-γ-induced atopic dermatitis-like HaCaT keratinocytes that realistically represent an in vitro model of atopic dermatitis (AD), anti-inflammatory responses of these collagens are evaluated. The expressions of pro-inflammatory cytokines and chemokines (IL-1β, IL-6, IL-8, RANTES, MDC, and TARC) are inhibited. Meanwhile, the CF15 series collagens suppress the activation of MAPKs signaling pathways. These results indicate that mucin-type CF15 series collagens have excellent potential as an alternative medicine for the treatment of AD and other skin-related inflammatory diseases. The innovative protein design employed in the construction of recombinant multicopy tandem mucin-type CF15 series collagens has the potential to advance the development of new types of collagen-dressing.